Trial Profile
Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Glycopyrrolate; Neostigmine
- Indications Neuromuscular blockade; Postoperative complications; Postoperative nausea and vomiting
- Focus Therapeutic Use
- Acronyms P-PERSoN
- 27 Mar 2023 Status changed from recruiting to discontinued.
- 26 Aug 2020 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
- 26 Aug 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2021.